Dinutuximab

Approved by the FDA on 10 March 2015, Dinutuximab (Unituxin®) is used in high-risk neuroblastoma pediatric patients who previously received multidrug treatment and benefited at least partially, together with stimulating factors such as GM-CSF, IL-2 and 13-RA. Neuroblastoma is a cancer originating in the nervous system, which carries messages from the brain throughout the body. Dinutuximab binds to a glycolipid molecule called GD2 on cancer cells, enabling their destruction.

This drug has numerous side effects, including pain, high fever, low blood pressure, low sodium, anemia, vomiting, diarrhea, low potassium and hives.